Bernat Olle, Ph.D.

Chief Executive Officer


Bernat Olle, Ph.D.

Chief Executive Officer

Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences.

In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

Ending the War on Microbes | Bernat Olle | TEDxCambridge


Bruce Roberts, Ph.D.

Chief Scientific Officer


Bruce Roberts, Ph.D.

Chief Scientific Officer

Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as Head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme where he directed pre-clinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis and autoimmunity. He also directed research efforts in support of several approved products including lemtrada, aubagio, thymoglobulin, Mozobil, alemtuzumab, leukine, chlofarabine and fludarabine and contributed to the generation of ecallantide.

Dr. Roberts has authored more than 50 peer-reviewed publications and contributed to several issued patents and patent applications. He received his PhD. in Biochemistry from the University of Ottawa, Canada.


Dan Couto

Chief Technical Officer


Dan Couto

Chief Technical Officer

Mr. Couto has 25 years of experience in biotechnology, biologics drug development and cGMP manufacturing, including at Merck Sharp Dohme Biologics UK (formerly Avecia Biologics) where he served as Vice President of Commercial Manufacturing Operations and was responsible for late stage and commercial manufacturing operations. In addition, Mr. Couto has held senior positions with several biotech companies including Nuvelo, Genzyme Transgenics and Advanced Biosystems and, most recently, was Senior Vice President of Manufacturing and Facilities Operations at ContraFect Corporation where he was responsible for chemistry & manufacturing controls, supply chain, quality assurance and facilities.

Mr. Couto holds multiple U.S. patents. He received his B.S. in Chemical Engineering from Rensselaer Polytechnic Institute.


Erik Spek, Ph.D., J.D.

VP, Head of Legal Affairs and IP


Erik Spek, Ph.D., J.D.

VP, Head of Legal Affairs and IP

Erik Spek is the head of Intellectual Property at Vedanta. Prior to his current position, Erik was Director of IP at Epizyme and worked at Boston-based IP law firm Wolf Greenfield. Erik graduated cum laude from Suffolk Law School in Boston. He earned his B.S. in Chemistry and Philosophy from Vrije Universiteit in Amsterdam and his PhD. in Biophysical Chemistry from New York University.


Debra Winslow

VP Program Management & Operations Planning


Debra Winslow

VP Program Management & Operations Planning

Deb Winslow has joined Vedanta after working in the biotech industry for over 25 years in various roles from early product development through commercialization.  She received a BS in biochemistry from UNH, an MBA from Bentley University, is a Regulatory Affairs Certified (RAC) professional and a Project Management Professional (PMP).  Her roles is to set up program management and operational planning systems to ensure successful program execution across the company.


Justin Chakma

VP Business Development & Strategy


Lou Vaickus, M.D. FACP

Interim Chief Medical Officer


Lou Vaickus, M.D. FACP

Interim Chief Medical Officer

Lou Vaickus, M.D. FACP, serves as Interim Chief Medical Officer of Vedanta. Dr. Vaickus is Chief Executive Officer and Founder of akta Pharmaceutical Development LLC (aktaPD®). Dr. Vaickus has served as Interim Chief Medical Officer at several biotech companies, most recently at Verastem, Inc. and InVivo Therapeutics Holdings Corp. Dr. Vaickus’ therapeutic areas of specialization include development of NCEs, biologics, biosimilars, and live biotherapeutic products in oncology, hematology, pulmonary and other fibrotic disorders, infectious diseases, autoimmunity, rare metabolic disorders, immunology and medical devices. He has over 30 years of experience that began as an academic scientist and practicing physician, then spanned into industry with preclinical, clinical, and globally marketed pharmaceutical products. In industry, Lou served as Vice President and Head of Clinical Development, Global Medicines Development and Affairs at Vertex Pharmaceuticals. Before joining Vertex, Dr. Vaickus was Chief Medical Officer of Tolerx, Inc. from 2002 to 2011. Previously, he served as Vice President of Clinical Research and later as Senior Vice President of Medical Affairs at Sunovion (formerly Sepracor, Inc.), Medical Director of Oncology/Immunology at EMD Serono (formerly Ares Serono), where he supervised clinical and medical affairs for Rebif®, and Associate Medical Director, Medical Director, and later Medical Marketing Director for the Rebif® Multiple Sclerosis Strategic Business Unit at Serono. Dr. Vaickus is board certified in Internal Medicine, Hematology, and Medical Oncology. He completed postdoctoral fellowships in hematology, oncology, and immunology at the Mayo Clinic and Stanford University. Dr. Vaickus has held faculty positions at the U of Iowa (Division of Hematology/Oncology) and at Roswell Park Cancer Institute/SUNY Buffalo (Divisions of Clinical Immunology, Bone Marrow Transplant, Hematologic Malignancies, and Solid Tumor Oncology and Investigational Therapeutics). Dr. Vaickus holds an M.D. from Loyola University's Stritch School of Medicine.


Tom Parrotta

Manager of Grants Administration and Accounts Payable


Brian Klein, Ph.D.

Staff Scientist I


James Llewellyn

Senior Research Associate


Jason Norman, Ph.D.

Senior Scientist


Colin Heberling

Senior Research Associate Bioinformatics


Gouri Vadali

Research Associate/Bioinformatics


Silvia Caballero, Ph.D.

Scientist II


Cintia Felix

Senior Research Associate


Krishnaveni Ramanan

Senior Research Associate


Allison Shottek

Research Assistant


Rose Szabady, Ph.D.

Senior Staff Scientist


Michael Mosho

Research Associate


Amanda Costa

Research Associate/Immunology


Shilpa Reddy

Principal Research Associate


Cherylyn Smith

Lab Manager


Amy Pepicelli

Research Associate


Ryan Busha

Senior Clinical Research Manager


Maria Kim

Clinical Trial Associate


Kris Ireland

Director of Manufacturing


Robert D’Orazio

Senior Manufacturing Associate


Steve Derby

Manufacturing Associate


Alicia Szretter

Manufacturing Supervisor


Scott Michonski

Manager of Process Development & Technical Operations, Upstream


Jil Ulrich

Manager of Process Development & Technical Operations, Downstream


Ketaki Nade

Analytical Development


Brian Howe

Facility Manager


Deb Rich

Senior Quality Consultant - Warren Cove Consulting, LLC


Evan Kustubardis

Senior QA Compliance Specialist


Dave Crane

QA Manager


Alex Buckley

Supply Chain Supervisor


Melissa Smith

Quality Consultant


Antonio Volpini

Research Associate, Platform


Brad White

Process Development Engineer


Connor Ball

Warehouse Associate


Dan Clarici

Manufacturing Associate


Diti Goradia

QA Associate


Jeff Autenrieth

Talent Acquisition


Jose Arias

Manufacturing Associate


Kathryn Dudley

EA & Executive Administrator


Kelsey Brown

Clinical Trial Associate


Marie Allen-Hadge

Senior Director of Quality


Meg Warsi

Office Coordinator


Rayssa Delorey

Technical Operations


Sally Byrne

Corporate Counsel